|
|
Article: Astellas' net income for full-year 2005 reaches 103.6 billion yen.(Astellas Pharma Inc.)
- Article from:
- Pharma Marketletter
- Article date:
- May 29, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Japanese drug major Astellas says that its operating income for the fiscal year ended March 2006, which edged up 0.4% to 193.0 billion yen ($1.72 billion), was below its target of 205.0 billion yen. The firm attributes the under-performance to lower-than-expected sales of several of its key products.
Despite missing its annual forecast, Astellas did see a steep increase in net income during the year, which hit 103.6 billion yen, up 74.1%. The company said that the income hike was thanks, in part, to a drop in its level of extraordinary expenses associated with the creation of the company via the merger of Yamanouchi and Fujisawa (Marketletters passim), which were ...